FindTrial
Sign In

Evaluation of Interventions by Pharmacists in Vancomycin Treatment in Chinese Adult Pneumonia Patients: A Randomized Controlled Trial

Evaluation of Interventions by Pharmacists in Vancomycin Treatment in Chinese Adult Pneumonia Patients: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021115
Enrollment
Unknown
Registered
2019-01-29
Start date
2017-01-05
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Interventions

Intervention group:population pharmacokinetics, therapeutic drug monitoring
Control Group:No

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. adult patients (age =18 years) at Peking University First Hospital; 2. patients who received intravenous vancomycin infusion for more than 2 days due to pulmonary infections (hospital acquired pneumonia, HAP; community acquired pneumonia, CAP); 3. patients who accept the informed consent.

Exclusion criteria

Exclusion criteria: 1. patients who had multiple organ failure, renal replacement therapy, chronic renal insufficiency level 4 or 5 or hypovolemic shock; 2. patients with incomplete clinical information due to personal reasons.

Design outcomes

Primary

MeasureTime frame
VI-AKI incidence rate;—

Secondary

MeasureTime frame
TDM detection rate;the rate of vancomycin trough concentrations within the desired target range;—

Countries

China

Contacts

Public ContactLi Yang

Peking University First Hospital

li.yang@bjmu.edu.cn+86 10 83572776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026